Sanofi faced a challenging quarter with declines in net income and revenues, especially in the Vaccines segment. While some new launches showed growth, overall performance lagged due to lower sales in core geographies and categories.

Sanofi delivered profitable growth in Q3 2025, with business EPS reaching €2.91 and total revenue of €12.43 billion. Net income remained stable, while Dupixent sales exceeded €4 billion for the first time. Vaccine sales declined due to flu-related weakness.

Sanofi delivered a solid Q2 2025 with 10.1% constant exchange rate sales growth and strong contributions from new product launches and immunology. Business EPS rose to €1.59, and net income more than tripled to €3.94 billion.

Sanofi delivered a solid Q1 2025 performance with 10.8% revenue growth and a 17% increase in non-GAAP EPS, supported by strong momentum in its pharma pipeline and immunology portfolio.